Pharmalot

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about AstraZeneca threatening the U.K., mpox vaccine distribution, and more

Pharmalot Adam Feuerstein

STAT Plus: Pharmalittle: We’re reading about a negative U.K. review of Leqembi, Bavarian Nordic’s strong earnings, and more

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about obesity drugs and suicidal thoughts, a FDA official’s conflicts, and more

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about Zepbound trial results, an Alnylam heart drug, and more

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about FTC scrutiny of a Novo deal, a Genentech reorganization, and more

Pharmalot Ed Silverman

STAT Plus: Will the FTC challenge a deal that would give Novo Nordisk control of some Catalent plants?

Pharmalot Ed Silverman

STAT Plus: Up and down the ladder: The latest comings and goings

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about a Covid-flu shot setback, mpox vaccine supplies, and more

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about Medicare drug savings, Lilly warning doctors, and more

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about an AstraZeneca U.K. vaccine plant, Medicare premiums, and more

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about Novartis losing bid to block a generic, pharma deals, and more

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about FDA rejecting MDMA; a nasal spray for allergic reactions, and more

Pharmalot Ed Silverman

STAT Plus: Up and down the ladder: The latest comings and goings

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about a California bill to restrain PBMs, a U.K. trade group scolding Novo, and more

Pharmalot Ed Silverman

STAT Plus: Medicare paid substantially more for J&J’s Stelara when it was covered under Part D than under Part B

Pharmalot Ed Silverman

STAT Plus: A U.K. trade group scolds Novo again — this time for remarks made by its CEO

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about a Purdue overdose-reversal device, a discontinued Merck trial, and more

Pharmalot Ed Silverman

STAT Plus: FDA scolds Bristol Myers over a misleading website for a cancer treatment

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about Roche plans for Flatiron, underwhelming Novo Nordisk earnings, and more

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about a canceled Roche trial, low VC biotech funding, and more

Pharmalot Ed Silverman

STAT Plus: North Carolina urges HHS to license Novo and Lilly obesity drugs as a way to lower costs

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about MDMA trials, weight loss drug availability, and more

Pharmalot Jonathan Wosen

STAT Plus: Pharmalittle: We’re reading about a soft-tissue cancer drug approval, the Zepbound shortage ending, and more

Pharmalot Andrew Joseph

STAT Plus: Pharmalittle: We’re watching positive Zepbound cardiovascular data, a move to take 23andMe private, and more

Pharmalot Allison DeAngelis

STAT Plus: Pharmalittle: We’re watching GLP-1 drug data in Alzheimer’s, a flu shot push for livestock workers, and more

Pharmalot Bob Herman and Ed Silverman

STAT Plus: Wells Fargo faces class action lawsuit over workers’ high drug costs

Pharmalot Ed Silverman

STAT Plus: NIH loses suit over censoring social media comments made by animal rights advocates

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about the U.K. nixing coverage for a cancer drug, sharing bird flu vaccine data, and more

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about Sarepta’s demand to censor a video, Roche fast-tracking an obesity pill, and more